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Background: While efforts to improve cancer outcomes have typically focused on improving quality of care,
recently, a growing emphasis has been placed on timely access to quality cancer care. This retrospective cohort
study examines, at a population level, the relationship between quality and timeliness of colorectal cancer (CRC)
care in a single Canadian province (Nova Scotia). Through the provincial cancer registry, we identified all residents
diagnosed with invasive CRC between 2001 and 2005 that underwent a non-emergent resection. Using
anonymized administrative databases that are individually linked at the patient level, we obtained
clinicodemographic, diagnostic, and treatment event data. Selected charts were reviewed to ensure completeness
of chemotherapy data.
Performance on six quality indicators and the percentage of patients achieving wait-time benchmarks for diagnosis,
surgery, and adjuvant therapy were calculated. The relationship between quality indicators and wait-time
benchmarks was examined using logistic regression.
Results: Where an association was identified, patients who received ‘higher quality care’ had longer wait times.
Individuals who received a complete preoperative colonoscopy were less likely to meet benchmarks for time from
presentation to diagnosis and from diagnosis to surgery. Those who received an appropriate radiation oncology
consultation were less likely to meet benchmarks for time from diagnosis to surgery and from surgery to adjuvant
therapy.
Conclusions: As governments and other organizations move forward with strategies to reduce wait times, they
must also focus on how to define and monitor quality care, and consider the relationship between these two
dimensions of health care. Similarly, when developing quality improvement initiatives, the impact on resource
utilization and potential to create longer waits for care must be considered.
Keywords: Colorectal neoplasms, Quality indicators, Healthcare quality, Access, EvaluationBackground
Colorectal cancer (CRC) is a highly prevalent cancer in
Canada and, despite decreased mortality in recent years, it
remains the third most frequent cause of cancer-related
mortality for both males and females [1]. Prognosis is
largely dependent on stage at diagnosis with an estimated
five-year relative survival ratio of 90% for early stage
(localized) CRC, and only 12% for metastatic disease [2].* Correspondence: Geoff.Porter@cdha.nshealth.ca
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reproduction in any medium, provided the orEfforts to improve CRC outcomes have typically focused
on improving quality of care, defined as “the degree to
which health services for individuals and populations
increase the likelihood of desired health outcomes and
are consistent with current professional knowledge” [3].
The measurement of the delivery of quality care has typ-
ically involved assessment of adherence to clinical prac-
tice guidelines (CPGs) and, more recently, performance
on CRC-specific quality indicators (QIs).
Recently, a growing emphasis has been placed on timely
access to quality cancer care [4-7]. Internationally, organiza-
tions have proposed wait-time benchmarks for various
aspects of cancer care in order to reduce wait times; mosttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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wait times often result from limited system capacity at
various points along the care trajectory (i.e., “bottlenecks”),
increasing the delivery of more timely care may require
additional resources, or the reallocation of existing re-
sources. As such, implementing standards to increase
timeliness may affect other aspects of care delivery,
such as performance on certain quality indicators.
In a previous study by McConnell et al. [14], the achieve-
ment of several CRC-specific QIs was associated with a
decreased likelihood of achieving certain wait-time
benchmarks in a single health district in Nova Scotia
(NS), Canada. For example, patients who received pre-
operative staging imaging were less likely to receive surgery
within 4 weeks of diagnosis. Based on these findings, the
objective of the current study was to further explore, at
a population level, the relationship between quality and
timeliness of CRC care in NS.Methods
Cohort
NS is a Canadian province comprised of nine health
districts with a population of approximately 900,000. A
population-based cohort of all individuals diagnosed
with invasive CRC in NS between 2001 and 2005 was
identified by the NS Cancer Registry (NSCR). From this lar-
ger cohort, our study included only those individuals who
had a non-emergent resection for primary CRC (n = 2282).
Individuals who presented to the emergency room and
were subsequently diagnosed with CRC via emergency
resection were excluded from this study as their treatment
did not align with usual processes involving referral,
investigation, and treatment. Patients who underwent
polypectomy surgery and stage IV patients with surgery
after chemotherapy were also excluded.Data sources
Using anonymized administrative databases that were
individually linked at the patient level, we obtained
clinicodemographic, diagnostic, and treatment event
data. Data were obtained from: the NSCR, the Canadian
Institute for Health Information Discharge Abstracts Data-
base (DAD; inpatient diagnoses and procedures performed),
Medical Services Insurance Physician Services (MSIPS; pro-
vincial physicians’ billing database that includes all physician
visits and procedures), and neighborhood-level national
2001 census data. The characteristics and linkage of these
databases has been published previously [15]. To ensure
completeness of chemotherapy data, a chart review was
performed on all stage II/III rectal and stage IIB/III
colon cancer patients for whom there was a medical
consultation, but no indication of chemotherapy receipt in
the administrative data to determine whether the patientactually received chemotherapy. Details on the chart re-
view are reported elsewhere [16].
Clinicodemographics
Clinicodemographic variables included age, sex, comor-
bidity, cancer history, tumor location and stage, rural/
urban residency, and length of stay (LOS) in hospital.
Comorbidity was quantified using a comorbidity score
(or count) based on the list of comorbid conditions de-
veloped by Elixhauser et al. [17]. Using the ICD-9 CM
and ICD-10 coding developed by Quan et al. [18], this
resulted in a list of 31 comorbidities, three of which were
cancer-specific (i.e., lymphoma, metastatic cancer, and
solid tumor without metastasis). To obtain a measure of
comorbidity independent of the patients’ current cancer
diagnoses (all patients had a confirmed diagnosis), the
three cancer-specific comorbidities were excluded from
the list, and each patient was assigned a comorbidity score
of 0 to 28. Previous cancer diagnoses were captured by
the cancer history variable, which contained a count of all
previous cancer diagnoses as contained in the NSCR.
All cases of CRC were staged using the Collaborative
Stage (CS) Data Collection System, version 1, resulting in
CS-derived AJCC TNM stage groups [19,20]. To define
patient residence as rural or urban, each patient’s residen-
tial postal code at diagnosis was assigned to a census dis-
semination area (DA) via the Postal Code Conversion File
Plus (PCCF+) [21], collapsed into census subdivisions, and
categorized based on classifications developed by Statistics
Canada [22]. Additional details on these variables are
provided elsewhere [15].
Quality indicators
Quality care was examined using a subset of the CRC-
specific QIs used by McConnell et al. [14]. Indicators were
included based on their presence within the literature
[23-27] and on the opinion of clinician team members that
these indicators could potentially impact timely access to
care. Given the study objective of exploring the relationship
between quality and access at a population level, QIs were
also selected based on their availability in linked adminis-
trative health databases in NS. Ultimately, six CRC-specific
QIs were included:
 Complete preoperative colonoscopy: Complete
preoperative large-bowel examination by colonoscopy,
identified using procedure codes within MSIPS.
 Margin status reported: Pathology reporting that
includes margin status, dichotomously classified
(i.e., yes/no). This information is collected as part
of the CS Data Collection System [19] and is
available from the NSCR.
 Adequate lymph node (LN) harvest: Pathology
reporting that includes examination of at least 12
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information is collected as part of the CS Data
Collection System [19] and is available from the NSCR.
 Peri-operative mortality: Death occurred in-hospital
or in the 30 days following resection, dichotomously
classified (i.e., yes/no). This information was
obtained from the NSCR and DAD.
 Appropriate radiation oncology consultation:
A pre-operative consultation for any rectal cancer
patient, or a post-operative consultation for patients
who did not receive neo-adjuvant radiotherapy and
had stage II or III rectal cancer. Radiotherapy data
was obtained from the NSCR.
 Appropriate medical oncology consultation:
A post-operative consultation for all stage II-IV CRC
patients. The inclusion of stage II-IV CRC patients
was based on the assumption that after resection,
regardless of curative or palliative intent (which
cannot be determined from administrative data),
these patients should receive at least a medical
oncology consultation. Chemotherapy data was
obtained from the NSCR, MSIPS, and chart review.
Wait-time intervals
Timeliness of CRC care was assessed using wait-time
benchmarks. This study used aggregates of existing
benchmarks [9,11,13]: 4 weeks from presentation to
clinical diagnosis, 4 weeks from clinical diagnosis to
surgery, 8 weeks from surgery to start of adjuvant ther-
apy. For each interval, the following start and end points
were defined:
 Presentation date was defined as the date of the
earliest physician visit for signs/symptoms suggestive
of CRC within 1 year prior to clinical diagnosis.
MSIPS was used to identify visits and associated
diagnostic codes. Diagnosis codes suggestive of CRC
included those related to gastrointestinal complaints
(e.g., diarrhea, anal or rectal pain, blood in stool),
anemia, weight loss, fatigue, and nausea/vomiting as
well as screening for malignancy of colon or rectum.
 Clinical diagnosis date was defined as the earliest of
the diagnosis date in the NSCR, or date of a
colonoscopy/sigmoidoscopy/ barium enema
performed within 3 months prior to surgery.
 Surgery date was defined as the earliest non- emergent
surgical resection as identified within the DAD and
MSIPS.
 (Neo) adjuvant therapy start dates were defined as the
first date (post-resection for adjuvant therapy) that a
patient received either chemotherapy or radiotherapy.
For patients who received neo-adjuvant radiotherapy,
the interval from clinical diagnosis to surgery was
adjusted by 10 weeks to account for the deliveryof radiotherapy and necessary recovery time prior
to surgery.
Analysis
Descriptive statistics were generated for clinicodemographics,
QIs, and time intervals. The denominator for all QIs, ex-
cept those related to oncology consultation, was the entire
study cohort (n = 2282). For the QIs related to appropriate
medical or radiation oncology consultation, the denomin-
ator included all patients for whom a consultation would
be considered appropriate, as described previously.
Multivariate logistic analyses were performed to explore
which clinicodemographics and QIs were associated with
meeting each of the wait time benchmarks. Only rele-
vant QIs were included in each model (i.e., those
representing activities that would have occurred in the time
up to and including that captured by each interval). For
each interval, the model included the following variables:
 Presentation to diagnosis: age group, sex,
comorbidity count, cancer history, rural/urban
residence, tumor location, and preoperative
colonoscopy. Tumor stage was not included as it
was not known prior to diagnosis.
 Diagnosis to surgery: age group, sex, comorbidity
count, cancer history, rural/urban residence, stage,
preoperative colonoscopy, and appropriate radiation
oncology consultation. Tumor location was not
included since separate models were run for CRC
and rectal cancer only.
 Surgery to adjuvant therapy: sex, age group,
comorbidity count, cancer history, rural/urban
residency, LOS, preoperative colonoscopy, margin
status reported, adequate LN harvest, peri-operative
mortality, appropriate radiation oncology consultation,
and appropriate medical oncology consultation. Only
those with a tumor stage for which adjuvant therapy is
recommended were included in this analysis. As such,
tumor stage was not included as a covariate.
Ethical approval for this study was obtained from the
Capital District Health Authority’s Research Ethics Board
(CDHA-RS/2008-049).
Results
Cohort clinicodemographics are presented in Table 1.
As shown in Table 2, performance varied substantially
across QIs. Notably, margin status was reported for
94.6% of the study cohort while adequate LN harvest
was obtained in only 31.8%.
With regard to wait-time benchmarks (Table 3), 37.1%
of patients achieved the 4-week benchmark from presenta-
tion to diagnosis; 67.4% achieved the 4-week benchmark
from diagnosis to surgery; and 39.2% achieved the
Table 1 Clinicodemographics (n = 2282)
Characteristic n %
Age < 50 yrs 147 6.4
50 - 69 yrs 935 41.0
≥ 70 yrs 1200 52.6
Sex Male 1259 55.2
Female 1023 44.8
Comorbidity count 0-3 2185 95.8
≥ 4 97 4.3
History of cancer Yes 339 14.9
No 1943 85.1
Tumor location Right colon 865 37.9
Left colon 579 25.4
Rectum 818 35.9
Colon NOS 20 0.9





Rural/urban Rural 876 38.4
Urban 1406 61.6
Length of stay (post-resection) Median (days) 9
Inter-quartile range (days) 5









1807 44 4 weeks 37.1
Diagnosis to
surgery- CRC2
2282 19 4 weeks 67.4
Diagnosis to
surgery-RC Only2
818 25 4 weeks 56.5
Surgery to
adjuvant therapy3
526 66 8 weeks 39.2
1Presentation date not available if there were no physician visits in the year
prior to diagnosis, or if no presentation codes present consistent with those
that we identified.
2For rectal cancer patients who received neo-adjuvant radiotherapy, this
interval was adjusted by subtracting 10 weeks from the total time between
diagnosis to surgery to account for the delivery of radiation and subsequent
recovery time prior to surgery.
3Contains stage II, III rectal cancer patients and stage III colon cancer patients
who received adjuvant therapy. (i.e., this includes both post-operative
chemotherapy and post-operative radiotherapy).
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therapy. When only rectal cancer patients were consid-
ered in the diagnosis to surgery time interval, 56.5%
achieved the 4-week benchmark.
Factors associated with meeting the wait-time bench-
marks are summarized in Table 4, where several asso-
ciations with QIs were identified. The receipt of a
preoperative colonoscopy was associated with a decreased
likelihood of meeting benchmarks for presentation to
diagnosis and diagnosis to surgery. The receipt of anTable 2 Quality indicator performance
Quality indicator n % achieved
Complete preoperative colonoscopy 2282 57.8
Margin status reported 2282 94.6
Adequate lymph node harvest (≥ 12) 2282 31.8
Peri-operative mortality 2282 2.7
Appropriate radiation oncology consultation 1 514 72.6
Appropriate medical oncology consultation 2 1772 60.9
1 All stage II, III rectal patients + rectal patients who had
preoperative consultation.
2 A post-operative consultation for all stage II to IV colorectal patients.appropriate radiation oncology consultation was associated
with a decreased likelihood of meeting benchmarks for
diagnosis to surgery (for CRC and for rectal cancer patients
only) and surgery to adjuvant therapy. An increased LOS in
hospital was also associated with a decreased likelihood of
meeting the surgery to adjuvant therapy benchmark. No
other associations between the achievement of wait time
benchmarks and QIs were identified (data not shown).
Discussion
Quality indicators
QIs are evidence-based quantitative measures of health
system performance and related outcomes that are useful
for documenting/monitoring the quality of care, making
comparisons over time and between institutions, and
supporting quality improvement [28]. In our examination of
CRC-specific QIs, we found substantial variation in perform-
ance across indicators and in comparison to the literature.
QI performance was highest for margin status reported,
which is expected given the importance of margin status as
a prognostic factor and as a determinant for additional sur-
gery or adjuvant therapy. Only 31.8% of the individuals in
the current study had adequate LN harvest, however, this
marks improved practice in NS. An audit of a single health
district, conducted in the 4 years before this study, revealed
that only 22.4% of patients had adequate LN harvest [29].
Subsequent knowledge translation activities, targeting sur-
geons and pathologists, led to an increase in adequate nodal
harvest rates in the audited district and in NS [30].
Performance for the remaining QIs identified poten-
tial areas for improvement. First, a large proportion of
patients did not receive a complete pre-operative col-
onoscopy. A complete colonoscopy is recommended to
identify synchronous polyps and/or tumors that might
have been undetected on radiographic investigation
Table 4 Multivariate analyses
Wait-time interval Significant factors n Benchmark
achievement (%)
OR 95% CI p
Presentation to diagnosis:
benchmark 4 weeks (n = 1807)
Rural/urban Urban 1112 35.1 1.0
Rural 695 40.4 1.2 1.0 1.5 0.03
Sex Male 969 40.3 1.0
Female 838 33.5 0.8 0.6 0.9 0.004
Complete preoperative
colonoscopy
NO 746 40.1 1.0
YES 1061 35.1 0.8 0.7 1.0 0.04
Diagnosis to surgery:
benchmark 4 weeks (n = 2282)
Age group Overall 0.004
> = 70 1200 66.4 1.0
50-69 935 69.2 1.4 1.1 1.7 0.001
< 50 147 64.0 1.1 0.8 1.6 0.59
Complete preoperative
colonoscopy
NO 962 72.5 1.0
YES 1320 63.7 0.7 0.6 0.9 0.001
Stage Overall <0.001
I 467 55.9 1.0
II 785 70.5 2.0 1.5 2.6 <0.001
III 712 69.0 2.1 1.6 2.8 <0.001
IV 275 78.2 2.5 1.8 3.5 <0.001




YES 373 49.6 1.0
NO 445 62.3 2.4 1.8 3.3 <0.001
Not relevant (Colon) 1464 73.5 3.3 2.6 4.3 <0.001
Diagnosis to surgery
(rectal patients only): benchmark
4 weeks (n = 818)
Age group Overall 0.02
> = 70 354 53.1 1.0
50-69 394 59.9 1.6 1.2 2.2 0.004
< 50 70 54.3 1.3 0.8 2.2 0.36
Stage Overall 0.001
I 216 52.8 1.0
II 215 59.1 2.3 1.5 3.8 <0.001
III 272 55.5 2.2 1.4 3.5 0.001
IV 91 68.1 1.8 1.1 3.1 0.03
UNK 24 33.3 0.7 0.3 1.7 0.38
Appropriate radiation
oncology consultation
YES 373 49.6 1.0
NO 445 62.3 2.7 1.8 4.0 <0.001
Surgery to adjuvant therapy:
benchmark 8 weeks (n = 526)




YES 236 29.7 1.0
NO 27 48.2 2.6 0.3 20.7 0.36
Not relevant (Colon) 263 46.8 1.8 1.2 2.6 0.004
Factors associated with wait-time benchmark achievement.
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surgical resection of the known index tumor. The pres-
ence of tumor obstruction preventing passage of the
colonoscope proximally may explain some, but unlikelyall, of the patients not undergoing full preoperative col-
onoscopy. Second, only 60.9% of CRC patients had an
appropriate medical oncology consultation, and 72.6%
received an appropriate radiation oncology consultation.
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care center located in an urban setting (82% and 81%
for medical and radiation oncology, respectively) [31],
thus, the differences between the two studies may reflect
differences in study populations.
Wait-time intervals
Importantly, the wait-time benchmarks presented in this
paper were recommended in Canada and elsewhere but
not officially endorsed as policy in NS during the study
period. The purpose of this paper is not to evaluate system
performance based on these benchmarks, but to illustrate
how various factors impact the timely delivery of care. As
noted by the United Kingdom’s National Health Service
[11], “Where patients wait longer, this should be because
of the needs of the diagnostic process or their personal
choice, not because of built-in delays in the system of care.”
In our study, increased wait times were evident not only in
the diagnostic period, but also throughout treatment.
Only about one-third of patients in the current study
were diagnosed within 4 weeks of presentation. As
discussed by McConnell et al. [14], the processes involved
in diagnosis are complex, involving expertise from a variety
of individuals (primary care, diagnostic imaging, surgery,
pathology), often translating into increased time. In a small
jurisdiction such as NS, capacity issues may cause increased
wait times for appointments, and delays in the processing
and reporting of laboratory and radiology results. This is
exemplified by our finding that individuals who received a
complete preoperative colonoscopy were less likely to meet
the benchmark for time from presentation to diagnosis.
Relevant to colonoscopy, capacity issues may be related
to an insufficient number of surgeons, endoscopes, or
available clinical space (i.e. endoscopy suites or operating
room space), to perform a high volume of colonoscopies.
Interestingly, rural residents were more likely to meet the
presentation to diagnosis benchmark suggesting increased
system capacity in the rural districts for certain processes
within the presentation to diagnosis interval.
In comparison to the presentation to diagnosis interval,
a greater proportion of patients met the benchmark for
the diagnosis to surgery interval (for both CRC and rectal
cancer). This is perhaps reflective of more clearly defined
processes and the involvement of fewer clinicians dur-
ing this interval. Nonetheless, CRC patients who had a
complete preoperative colonoscopy were less likely to
meet the benchmark, as were rectal cancer patients who
received an appropriate radiation oncology consultation,
highlighting the impact of the involvement of multiple
(and appropriate) clinicians on wait-times. In terms of
clinicodemographics, age and stage affected benchmark
achievement. For both CRC and rectal cancer patients,
older individuals (≥70 years) were less likely to meet
the diagnosis to surgery benchmark, suggesting a moreaggressive approach to treating younger individuals. Simi-
larly, stage IV CRC patients were more likely to meet the
benchmark; however, for rectal cancer patients, stage II
patients were more likely to meet the benchmark.
Finally, the surgery to adjuvant therapy interval was
negatively associated with LOS and receipt of an appropri-
ate radiation oncology consultation. The effect of LOS
in hospital is indicative of surgical complications, from
which recovery time is required prior to beginning ad-
juvant therapy.
Overall, most of the analyses did not show a significant
association between QI performance and achieving wait-
time benchmarks. Where an association was identified,
patients who received ’higher quality care’ had longer wait
times. Specifically, individuals who received a complete pre-
operative colonoscopy waited longer for a diagnosis and for
surgery, and those who had an appropriate radiation on-
cology consultation waited longer for both surgery and ad-
juvant treatment. In these instances timeliness is
appropriately sacrificed to ensure each individual receives
quality care, as defined by these specific quality indicators.
Limitations
The use of administrative data allowed us to examine
the relationship between access to and quality of care at
a population level, however, there are a number of limi-
tations associated with the approach. Given the nature
of administrative data, we were unable to assess the effect
of patient decision-making on either QI or timeliness
benchmarks, which could potentially affect the quality and
timeliness of the care received. For example, individuals
may choose not to have a colonoscopy or an oncology
consultation, or may schedule appointments around other
commitments. In addition, our definition of presentation
date was based on administrative codes from physician
visits. Although this approach has been used in similar
studies of CRC [32,33], we could not identify a presentation
date for all patients. It should also be noted that due to the
use of the DAD (i.e., hospital discharge data) to compute
co-morbidity, our co-morbidity count is conservative and
may underestimate the number of co-morbidities present.
Given that population-based imaging data were unavailable,
this study could only examine the proportion of patients
who received a preoperative colonoscopy, not those who
may have received a complete bowel examination via bar-
ium enema + flexible sigmoidoscopy.
While this was a large population-based study, the
common (or uncommon) nature of some of the quality
indicators (e.g. margin status) and/or the small size of
some subgroups (e.g. rectal cancer patients eligible for
radiotherapy consultation) may limit the power of these
analyses. Finally, this study is part of a broader body of
work using administrative data based on patients diagnosed
between 2001 and 2005. As such, the data used in this
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performance or benchmark achievement). However, the
purpose of this study was not to evaluate cancer system
performance in NS, but to demonstrate the complex con-
ceptual relationship between measures of access and quality
of care, which remains relevant in the NS context wherein
resource and capacity issues are prevalent.
Conclusion
The relationship between quality of and timely access to
care is complex. For individuals with CRC, where an
interdisciplinary approach to care is necessary, the various
individuals and processes involved along the care con-
tinuum lead to inherent system waits. These waits may be
amplified as challenges in treatment arise as a result of
disease histology, patient comorbidity, or toxicity. Thus,
increased wait times may be appropriate and help ensure
the patient receives high quality care.
At the system level, we rely on metrics such as QIs
and wait-time benchmarks to evaluate performance.
Arguably, however, recent political emphasis has been on
wait times and setting/achieving wait-time benchmarks
rather than on monitoring processes of care that reflect
quality (e.g., QIs). As governments and other organizations
continue to move forward with strategies to reduce wait
times, our findings suggest they must also focus on defining
quality care, establishing mechanisms to identify and moni-
tor quality care, and giving thoughtful consideration to the
relationship between these two dimensions of health care.
Similarly, when developing quality improvement initiatives,
the impact on resource utilization and potential to create
longer wait times for care must be considered. In other
words, we must beware of setting standards that we do not
have the system capacity to achieve.
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